Association Between Cancer and Anti-synthetase Syndrome
NCT ID: NCT04941547
Last Updated: 2021-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-04-01
2021-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Peripheral Neutrophils in Antisynthetase Syndrome
NCT05691725
Juvenile Autoimmune Necrotizing Myopathies
NCT04295785
Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
NCT05984394
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
NCT06004817
Multicenter Cohort Study of AAV in Hunan of China
NCT05315141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* positive antisynthetase antibodies (JO-1,PL12, PL17, EJ, OJ, KS, RS, YRS)
Exclusion Criteria
* opposition to data collection
* no positive antisynthetase antibodies
* absence of clinical involvment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
CHU de Reims
OTHER
University Hospital, Strasbourg, France
OTHER
Hopitaux Prives de Metz, Groupe UNEOS
OTHER
Centre Hospitalier Universitaire de Besancon
OTHER
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Moulinet, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU de Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Moulinet
Vandœuvre-lès-Nancy, Lorraine, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021PI055
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.